Improvement of electrical features of SnO2 based varistor doped with Al2O3

Abdul-Ridha, Zainab S.; Al-Jasim, Ali A. N.; Radam, Ali O.

doi:10.1063/1.5117024

Cited by 1 publication

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to trace amines, receptors can be activated by amphetamine-like psychostimulants, and endogenous thyronamines. Labelled ligands [ 3 H]tyramine (Agonist) [244] Comments: In addition to TA 1 , in man there are up to 5 functional TAAR genes (TAAR2, 5,6,8,9). See [244] for detailed discussion.…”

Section: Commentsmentioning

confidence: 99%

“…13 ,Nle 14 ]bombesin-(6)(7)(8)(9)(10)(11)(12)(13)(14) [1050] compound 9g[1672,2131, 2134], MK-7725[438], MK-5046[1792,2327], [D-Tyr 6 ,Apa-4Cl 11 ,Phe13 ,Nle 14 ]bombesin-(6-14) [1643], compound 17c [1671], bag-1 [888], compound 22e [977] Antagonists D-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Nal-NH 2 (pIC 50 6.2-6.6) [841] --Selective antagonists PD 176252 (pIC 50 9.3-9.8) [841], PD 168368 (pIC 50 9.3-9.6) [841], dNal-cyc(Cys-Tyr-dTrp-Orn-Val)-Nal-NH 2 [D-Phe 6 , Leu 13 , Cpa 14 ,ψ13-14]bombesin-(6-14) (pK i 9.8) [841], JMV641 (pIC 50 9.3) [2590] -Mouse, [(3-Ph-Pr 6 ), His 7 ,D-Ala 11 ,D-Pro 13 ,y13-14),Phe 14 ]bombesin-(6-14) (pIC 50 9.2) [841, 1445], JMV594 (pIC 50 8.9) [1556, 2590] -Mouse, [D-Tpi 6 , Leu 13 y(CH 2 NH)-Leu 14 ]bombesin-(6-14) (pIC 50 8.9) [841], [D-Phe 6 , Stat 13 , Leu 14 Bn(6-14) (pIC 50 8.1) [1641] bantag-1 (pIC 50 8.6-8.7) [888, 1792, 2132], ML-18 (pIC 50 5.3) [1783] Labelled ligands [ 125 I]BH-NMB (human, mouse, rat) (Agonist), [ 125 I] [Tyr 4 ]bombesin (Agonist) [ 125 I][D-Tyr 6 ]bombesin-(6-13)-methyl ester (Selective Antagonist) (pK d 9.3) [1642] -Mouse, BAY86-7548 (Antagonist) (pIC 50 8.6) [1199, 2625], [ 125 I][Tyr 4 ]bombesin (Agonist) [178], BAY86-7548 (Selective Antagonist) (pIC 50 8.1) [1387, 1640, 1641], [ 125 I]GRP (human) (Agonist) [ 125 I]bantag-1 (Selective Antagonist) (pK i 9.6) [2132], [ 3 H]bag-2 (Agonist) [888] -Mouse, [ 125 I][D-Tyr 6 ,b-Ala 11 ,Phe 13 ,Nle 14 ]bombesin-(6-14) (Agonist)[1644,1792] Comments:…”

mentioning

confidence: 99%

“…50 9.3-10.4)[1579] -Rat, DMP696 (pK i 8 [3][4][5][6][7][8][9]. [976], NBI27914 (pK i 8.3-9)[397], R121919 (pK i 8.3-9)[2961], antalarmin (pK i 8.3-9)[2756], NBI-35965 (pK i 8.4)[1744] -Rat, CP 376,395 (pIC 508.3) [415] -Rat, CRA1000 (pIC 50 6.4-7.1)[378] antisauvagine (pK d 8.8-9.6)[530], K41498 (pK i 9.2)[1423], astressin 2B (pIC 50 8.9)[2187], K31440 (pK i 8.7-8.8)[2226] …”

mentioning

confidence: 99%

See 2 more Smart Citations

The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors

Alexander,

Christopoulos,

Davenport

et al. 2023

British J Pharmacology

View full text Add to dashboard Cite

The Concise Guide to PHARMACOLOGY 2023/24 is the sixth in this series of biennial publications. The Concise Guide provides concise overviews, mostly in tabular format, of the key properties of approximately 1800 drug targets, and about 6000 interactions with about 3900 ligands. There is an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (https://www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. Although the Concise Guide constitutes almost 500 pages, the material presented is substantially reduced compared to information and links presented on the website. It provides a permanent, citable, point‐in‐time record that will survive database updates. The full contents of this section can be found at http://onlinelibrary.wiley.com/doi/bph.16177. G protein‐coupled receptors are one of the six major pharmacological targets into which the Guide is divided, with the others being: ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading. The landscape format of the Concise Guide is designed to facilitate comparison of related targets from material contemporary to mid‐2023, and supersedes data presented in the 2021/22, 2019/20, 2017/18, 2015/16 and 2013/14 Concise Guides and previous Guides to Receptors and Channels. It is produced in close conjunction with the Nomenclature and Standards Committee of the International Union of Basic and Clinical Pharmacology (NC‐IUPHAR), therefore, providing official IUPHAR classification and nomenclature for human drug targets, where appropriate.

show abstract

Section: Commentsmentioning

confidence: 99%